Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

288
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
288
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

165
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
165
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

291
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
291

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative research and innovation strategy for rare diseases. Insights from the 5-year European joint programme on rare diseases, including analysis to inform recommendations for future actions.

Health research policy and systems·2025
Same author

Spanish Validation of the Autism Spectrum Quotient for Children (AQ-Child-SV).

Journal of autism and developmental disorders·2025
Same author

Pushing the boundaries of rare disease diagnostics with the help of the first Undiagnosed Hackathon.

Nature genetics·2024
Same author

Clinical and genetic characterization of patients with eye diseases included in the Spanish Rare Diseases Patient Registry.

Orphanet journal of rare diseases·2024
Same author

Psychosocial impact at the time of a rare disease diagnosis.

PloS one·2023
Same author

Management of hypocalcemia following thyroid surgery in children.

Frontiers in pediatrics·2023

Related Experiment Video

Updated: Feb 17, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.7K

Rare Disease Biospecimens and Patient Registries: Interoperability for Research Promotion, a European Example:

Yaffa R Rubinstein1, Manuel Posada de la Paz2, Marina Mora3

  • 1National Information Center of Health Services Research & Health Care Technology, National Library of Medicine/National Institute of Health, Bethesda, MD, 20892-1851, USA. yaffa.rubinstein@nih.gov.

Advances in Experimental Medicine and Biology
|December 8, 2017
PubMed
Summary

High-quality rare disease samples and data are vital for research. Consortia like EuroBioBank and Spain

Keywords:
BiobankBiological samplesBiospecimensData sharingGUIDRegistry

More Related Videos

Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

6.9K
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.7K

Related Experiment Videos

Last Updated: Feb 17, 2026

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.7K
Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

6.9K
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.7K

Area of Science:

  • Biomedical Research
  • Rare Diseases
  • Biobanking

Background:

  • Well-annotated specimens are critical for rare disease (RD) diagnostics and research.
  • Established consortia facilitate access to rare biological samples and data.
  • EuroBioBank (established 2001) and Spain's RDR and BioNER are key initiatives.

Purpose of the Study:

  • To highlight the importance of biobanks and registries for rare disease research.
  • To showcase successful models of rare disease sample and data management.
  • To emphasize the need for future interconnection and ethical data handling.

Main Methods:

  • Review of existing rare disease biobank networks and registries.
  • Description of the EuroBioBank network's services.
  • Explanation of the integrated model of Spain's National Rare Disease Registry (RDR) and Biobank (BioNER).

Main Results:

  • EuroBioBank pioneered European RD biobanking services.
  • The RDR and BioNER integration links patient samples with clinical data.
  • These initiatives enhance research accessibility to rare disease resources.

Conclusions:

  • Interconnected biobanks and registries are essential for future rare disease research.
  • Improved data discovery and accessibility are key goals.
  • Adherence to ethical and legal standards is paramount for participant privacy and data security.